Aberdeen Group plc Sells 6,077 Shares of Labcorp Holdings Inc. $LH

Aberdeen Group plc reduced its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 8.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,544 shares of the medical research company’s stock after selling 6,077 shares during the quarter. Aberdeen Group plc owned 0.08% of Labcorp worth $19,381,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of LH. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Labcorp by 7.7% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 158,231 shares of the medical research company’s stock valued at $41,537,000 after buying an additional 11,262 shares during the period. Lazard Asset Management LLC boosted its holdings in Labcorp by 224.1% in the second quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock valued at $259,734,000 after acquiring an additional 684,153 shares during the last quarter. Franklin Resources Inc. increased its position in Labcorp by 3.1% during the 2nd quarter. Franklin Resources Inc. now owns 34,331 shares of the medical research company’s stock valued at $9,012,000 after purchasing an additional 1,043 shares during the period. New York State Common Retirement Fund raised its holdings in Labcorp by 12.0% during the 3rd quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company’s stock worth $12,859,000 after purchasing an additional 4,800 shares during the last quarter. Finally, Independent Advisor Alliance lifted its position in shares of Labcorp by 166.6% in the 3rd quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company’s stock worth $3,477,000 after purchasing an additional 7,568 shares during the period. Institutional investors own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LH. Robert W. Baird boosted their target price on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday. Finally, Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and an average target price of $302.75.

More Labcorp News

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Analysts raised targets and ratings — JPMorgan bumped its price target to $330 and kept an “overweight” call, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Robert W. Baird raised its target to $326 and maintains an “outperform” rating, supporting the bullish analyst tone. The Fly
• Positive Sentiment: Q4 EPS beat — Labcorp reported adjusted EPS of $4.07 versus the ~$3.95 consensus, reflecting ~18% EPS growth year‑over‑year and supporting margin/earnings momentum. Earnings Report
• Positive Sentiment: FY‑2026 guidance is constructive — Labcorp provided adjusted EPS guidance of $17.55–$18.25 and revenue guidance of $14.61B–$14.79B, with management citing strong demand for diagnostics and investments in specialty testing and lab capacity. Press Release
• Neutral Sentiment: Brokerage consensus and thematic coverage — Coverage summaries label Labcorp a “moderate buy” and highlight value/style scores (Zacks), which supports steady institutional interest but is not a near‑term catalyst. Consensus Coverage Zacks
• Neutral Sentiment: Earnings call and deep dives available — Transcripts and analyst deep dives provide more color on volume trends, specialty testing growth and hospital partnerships for investors doing diligence. Deep Dive Transcript
• Negative Sentiment: Revenue missed estimates — Q4 revenue came in at $3.52B vs. ~ $3.56B expected, prompting some investor caution and a short‑term pullback in premarket trading. Seeking Alpha

Insider Transactions at Labcorp

In other news, CEO Adam H. Schechter sold 5,273 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total transaction of $1,499,535.74. Following the transaction, the chief executive officer directly owned 87,343 shares in the company, valued at approximately $24,838,602.34. This represents a 5.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. This represents a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Trading Up 0.9%

Shares of LH opened at $279.10 on Thursday. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The company has a market capitalization of $23.14 billion, a P/E ratio of 26.68, a P/E/G ratio of 1.72 and a beta of 1.03. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.35. The firm’s 50 day simple moving average is $264.77 and its 200 day simple moving average is $268.99.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s payout ratio is 28.29%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.